Carvykti, una terapia CAR-T desarrollada en China, está creciendo rápidamente en el mercado global 🌍

Las ventas alcanzaron $1.887B en el tratamiento del mieloma múltiple 📈

¿Cómo logró crecer tan rápido?
Mira el video 🔽

#Carvykti #CART #MultipleMyeloma #Oncology #Biotech

Le marché actuel du #MyélomeMultiple 🩸 #CAR_T 🧬 est dominé par deux thérapies uniquement #BCMA issues de grands leaders pharmaceutiques :

• #Abecma (ide-cel) biographie #BristolMyersSquibb 🇺🇸 & #2seventy 🇬🇧
• #Carvykti (cilta-cel) #JohnsonAndJohnson 🇺🇸 & #LegendBiotech 🇺🇸

CARVYKTI® Shows Promise for Sustained Remissions in Multiple Myeloma Patients after 2.5 Years Recent results from Johnson & Johnson's CARTITUDE-4 study reveal that CARVYKTI® has led to significant treatment-free remissions in multiple myeloma patients for up to 2.5 years.

CARVYKTI® Shows Promise for Sustained Remissions in Multiple Myeloma Patients after 2.5 Years #USA #Johnson_&_Johnson #Orlando #Multiple_Myeloma #CARVYKTI

🔴 "Il s’agit d’un traitement qui change la pratique. Il a changé la barre de ce que nous attendons pour les taux de réponse. Historiquement, les thérapies ont été approuvées sur la base de taux de réponse de 30 %, et là nous approchons d’un taux de réponse de 100 %"

#CAR_T #Carvykti #BCMA #FDA

Informative article overall, but could interrogate more deeply the idea pharma companies simply must charge outrageous prices to make money off drugs serving small # of patients.
#CARVYKTI generated over half a billion($USD) in sales in Q3 2025 alone (1.332billion ytd).
Literally a blockbuster drug.

Hematology Weekly News – September 8th 2025 🔬🩸 Hematology Updates: Functional Cure Signals, Head-to-Head CAR-T, Outpatient Bispecifics, BTK Approval, and More From five-year MRD-negative remissions in myeloma […] The post Hematology Weekly News – September 8th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Hematology Weekly News – September 8th 2025 #News #AML #Carvykti #CellCentric #Ciltacel Comment below!

J&J tests direct CAR-T marketing with first Carvykti ad The new direct-to-consumer ad signals J&J’s confidence in its capacity to meet demand for the cell therapy after earlier manufacturing struggles.

✨ #JohnsonAndJohnson teste le marketing direct #CAR_T 🧬 avec la pub #Carvykti
La pub s’adressant aux consommateurs, qui sera diffusée sur des services de #Streaming comme #Paramount, vise à sensibiliser les patients atteints de #MyélomeMultiple 🩸 au #CAR_Tcell 🧬
www.biopharmadive.com/news/carvytk...

...received #Carvykti #CAR-T in November of last year. After 60 days, I was in remission! Any folks fighting #cancer or #myeloma who want to use a hashtag like #cancersky to chat?

CARVYKTI® Provides Long-Term Remission for Multiple Myeloma Patients in Groundbreaking Study New data reveals that a single infusion of CARVYKTI® leads to five-year treatment-free remissions in patients with relapsed multiple myeloma. Discover its groundbreaking impact.

CARVYKTI® Provides Long-Term Remission for Multiple Myeloma Patients in Groundbreaking Study #United_States #Chicago #Johnson_&_Johnson #Multiple_Myeloma #CARVYKTI

Carvykti (Ciltacabtagene autoleucel)  | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento Infarmed

Carvykti (Ciltacabtagene autoleucel) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento
➡ swki.me/8CvhcD42

#infarmed #medicamentos #financiamentopúblico #carvykti

Johnson & Johnson showcases latest advancements in cancer innovation with more than 70 clinical and real-world studies at ASCO and EHA New CARVYKTI® data help shift the treatment paradigm in relapsed or refractory multiple myeloma with five-year progression-free survival rates Late-breaking AKEEGA® data selected for ASCO Press Progra...

Johnson & Johnson drops a clinical bombshell at #ASCO25 & #EHA2025 — over 70 cancer studies showcased, including game-changing 5-year PFS data for #CARVYKTI in tough-to-treat myeloma. Innovation that might rewrite the rules. #TCSC #CancerResearch #Myeloma #jnj

www.jnj.com/media-center...

Hey #cancer folks: would love to connect with other #multiplemyeloma patients. Especially if you've had multiple lines of treatment fail like I have. I'm currently on #Carvykti CAR-T treatment. It's been a rollercoaster with multiple crazy side effects. #myeloma #patient

Welp. Had sudden onset numbness and drooping on the left side of my face Wednesday night. Called the transplant team, went to the ER. Had CT scan and MRI with and without contrast. Pain was awful but is now under control. No sign of stroke! 💪

#cancer #multiplemyeloma #myeloma #carvykti

CARVYKTI® Shows Promise in Treating Multiple Myeloma with Significant MRD Negativity Rates Johnson & Johnson has reported significant findings from the CARTITUDE-4 study, where CARVYKTI® led to remarkably higher MRD negativity rates in multiple myeloma patients compared to standard therapies.

CARVYKTI® Shows Promise in Treating Multiple Myeloma with Significant MRD Negativity Rates #USA #San_Diego #Johnson_&_Johnson #Multiple_Myeloma #CARVYKTI

As a GMO, I had to wear the shirt! I'm at the cancer center for my daily checkup, blood work, and cognitive testing. I've had a bit of a headache, but other than that, I'm doing well! The cytokine release syndrome has cleared up completely.

#cancer #Carvykti #myeloma #multiplemyeloma

Checking in. I'm +10 days after #Carvykti. I was admitted to the hospital on day +8 for CRS, but was out in a day and a half. Dexamethasone brought the inflammation down. I didn't need Toci. I'm in the clinic for my daily blood tests and cognitive testing.

#cancer #multiplemyeloma #myeloma

Good news! The medical treatment (steroids) were effective. I had to fight my doc to start at a low dose, since I almost always have a negative reaction to #dexamethasone. He agreed to start me at 5 mg, and it was totally effective. I feel better, and I'm being released.
#cancer #myeloma #carvykti

Welp. Totally expected it, but I have had a reaction to the #Carvykti CAR-T treatment. Fever of 101.5, body aches, skull crushing headache, etc. Again, this is expected, but... Ouchies! I was admitted to a room at SAMC at about 3 this morning.

#cancer #multiplemyeloma #myeloma

Day +7 after #carvykti CAR-T treatment for #multiplemyeloma. Definitely feeling a bit of a headache today, feeling puny. But overall, moving forward nicely. As a genetically modified organism, I had to wear the shirt! 😆🤣😂

#cancer #myeloma

Day +6 after CAR-T treatment. Getting my blood work and cognitive tests. Almost no side effects so far. I keep waiting for the other show to drop. 😬

#cancer #carvykti #multiplemyeloma #myeloma

Day +4 after #Carvykti CAR-T treatment. No side effects except for my tummy is a little sensitive and I'm slightly fatigued. Just leaving the doctor's office for my daily check-in - blood work and neurological/cognitive checks. So far, so good! #cancer #multiplemyeloma #myeloma

Checking in at the St Davids Cancer center for my daily checkup after #carvykti multiple #myeloma #cancer. Day +3 after the CAR-T treatment.

Today I got CAR-T treatment with #Carvykti. It was, blessedly, anticlimactic. I didn't have a negative reaction, and it was a relatively short day. Now, we wait for any side effects. People have side effects around the second and third week.

By way of introduction, I am a cancer patient fighting #multiplemyeloma. I would love to connect with other #cancer patients on here. It seems a lot less toxic than other social media platforms. I'm scheduled to take Carvykti in 2 weeks. #myeloma #carvykti

I have a slot for CAR T-Cell therapy. My T cells will be collected in January. I'm relieved/terrified. #Carvykti